Q1 FY27 Results: Net Profit up 22% YoY at Rs 11.07 cr; Revenue grows 22%

Revenue Growth 20pctResults View source PDF Explain this filing

GUJTHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.3%Reaction day

₹359.70

prior close

₹361.55

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.0%-1.3% vs market

Pharmaceuticals peers, median of 167sector+0.3%-1.6% vs sector

On the reaction day the stock moved 1.3 pts less than Nifty Microcap 250 and 1.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

-0.5

15m

-0.9

30m

-1.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.3+0.0-1.3+0.3-1.6

Next day

+2.7-0.0+2.7+0.7+2.0

+0.9-0.2+1.1+0.6+0.3

-2.1+0.2-2.3+0.5-2.6

-3.5+0.3-3.9+1.2-4.8

-2.8+0.4-3.2+0.2-3.0

+4.2+0.9+3.3+0.2+4.1

15d

+14.0+1.6+12.4+0.8+13.2

+19.3+2.0+17.3+2.4+16.9

+5.6+0.6+5.1+1.6+4.0

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved unaudited Q1 FY27 results. Income from operations rose 22% YoY to Rs 43.79 cr (vs Rs 35.87 cr). Net profit grew 22% YoY to Rs 11.07 cr (vs Rs 9.06 cr). EPS at Rs 1.02 vs Rs 0.83. Total expenses at Rs 28.76 cr. Sequentially, PAT up 1.6% QoQ. Company set up two wholly-owned subsidiaries in Japan and Ireland, yet to start operations. Auditor gave unmodified review report.

Likely market impact

Strong YoY growth in revenue and profit driven by pharmaceutical intermediates and API business. Subsidiaries add future growth optionality.